Mastercard is implementing an agent-payment method that uses the x402 protocol and USDC stablecoin, with transactions settled on the Base blockchain network. This approach was tested in Mastercard's earlier Agent Pay pilot, which demonstrated nine payments using x402 for payment requests and Base for onchain settlement. The x402 protocol allows digital services to send HTTP 402 payment requests, enabling agents to sign vouchers within approved limits, which providers can later redeem collectively. This integration highlights Mastercard's move to embed specific tokens and blockchain networks into payment methods, potentially enhancing payment efficiency and security.
Mastercard's new payment method using x402 and USDC on the Base blockchain is notable technology news. For readers following the cryptocurrency market, here is Pluang's market snapshot as of Oct 24, 2026 21:01 WIB: out of 50 major cryptocurrencies, 5 rose and 43 fell. Among them, BAL rose 11.14% to Rp16.297 and EOS increased 8.13% to Rp12.649, while BAT dropped 8.03% to Rp2.887 with a strong sell order activity of 84%.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
